Erbitux slightly boosts survival in cancer study

(AP) -- Adding the novel cancer drug Erbitux to standard chemotherapy helped advanced lung cancer patients live just a month longer than chemo alone, a study found.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news131514196.html">Erbitux slightly boosts survival in cancer study</a></p> <p>(AP) -- Adding the novel cancer drug Erbitux to standard chemotherapy helped advanced lung cancer patients live just a month longer than chemo alone, a study found.</p>